Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/

Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/

Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/

Posted: 19 Mar 2020 12:00 AM PDT

There may be certain factors that put a patient with myelofibrosis at a higher risk for pulmonary hypertension, according to Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR.

Lopez-Mattei, a multimodality imaging cardiologist and associate professor of cardiology and diagnostic imaging at The University of Texas MD Anderson Cancer Center, was the lead author of an analysis that examined 143 patients with myelofibrosis who received an echocardiograph. Fourteen percent had findings that were consistent with pulmonary hypertension.

Patients at Higher Risk


Findings showed that females and those with N-terminal prohormone brain natriuretic peptide (BNP) were significant predictors of hypertension. Lopez-Mattei explained that there is an underestimation of pulmonary hypertension due to left-side heart disease, so evaluating respiratory symptoms and elevated N-terminal prohormone BNP should prompt an echocardiogram.

"We did a deep dive looking at the diastolic parameters, or the relaxation parameters, by echocardiogram to asses whether these patients could have some sort of pulmonary hypertension or secondary to left heart disease (LHD) because of the risk factors of the age range that these patients tend to have," Lopez-Mattei said in an interview with OncLive, a sister publication of Oncology Nursing News.

"We found that the most common cause of pulmonary hypertension was secondary to LHD or diastolic dysfunction permanently, which is not a surprise based on the comorbidities of the patients in our study."

Patient characteristics that were associated with pulmonary hypertension included:

  • Older age
  • Coronary artery disease
  • Larger left atrium

There were similar risk factors between patients with heart failure who have preserved ejection fraction and pulmonary hypertension.

"However," Lopez-Mattei added, "they also have the parameters that are the surrogates of the diastolic function that are abnormal in the majority of patients with pulmonary hypertension. If you put all of that into context, then you can understand why we have to look at patient risk factors regardless of whether or not they have myelofibrosis, because sometimes they need better blood pressure control."

Pulmonary Hypertension May Affect Outcomes


Lopez-Mattei said that there is a higher mortality signal in patients with myelofibrosis who also have pulmonary hypertension.
But having the comorbidity does not usually affect the treatment that these patients receive for myelofibrosis.

"In some patients with MPNs, there are some drugs that could cause some cardiovascular adverse events. We did not find that any [drugs] in pulmonary hypertension were tied to worsening outcomes," Lopez-Mattei said.

It is important that the oncology team works with a cardiology team to best treat patients with myelofibrosis and pulmonary hypertension.

"We have a close collaboration with pulmonologists because we both take care of this patient. Our [collaborative] approach has a lot of success because we have varied perspectives," Lopez-Mattei said.

A version of this article was originally published on OncLive as, "Multidisciplinary Approach Required for Pulmonary Hypertension in Myelofibrosis."

Comments

Post a Comment

Popular posts from this blog

Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News

Image
Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Growing Doubt, Uncertainty Over PDE5i Use in Left Heart Disease - Medscape AnMed Health gains national recognition through the Pulmonary Hypertension Association - WSPA.com Novitium's Generic Sildenafil for PAH Treatment Approved by FDA - Pulmonary Hypertension News Posted: 12 Jun 2019 05:00 AM PDT The U.S. Food and Drug Administration (FDA) has approved Novitium Pharma 's generic sildenafil for oral suspension at a dose of 10 mg/mL for the treatment of pulmonary arterial hypertension (PAH). This product, which had been designated a competitive generic therapy by the FDA, is the first approved generic equivalent to Pfizer 's Revatio , a vasodilator agent that induces blood ves...
Read more

Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor

Image
Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Epoprostenol Via High-Flow Nasal Cannula Improves Severe Hypoxemia in PH - Pulmonology Advisor Posted: 11 Jul 2019 12:00 AM PDT For patients with severe hypoxemia with pulmonary hypertension or right heart dysfunction, inhaled epoprostenol through high-flow nasal cannula increases oxygenation, according to a study published in Pharmaceutics . The researchers of this retrospective study assessed the effect of inhaled epoprostenol using a high-flow nasal cannula on oxygenation and future mechanical ventilation in patients with hypoxemia comorbid with pulmonary hypertension or right heart dysfunction in an intensive care unit setting. A chart review was completed on adult patients who were admitted into the respiratory care department of the Rush University Medical Center for severe hypoxemia between July 2015 and April 2018 and treated with inha...
Read more

Analysis: Large pharma companies do little new drug innovation - STAT

Image
Analysis: Large pharma companies do little new drug innovation - STAT Analysis: Large pharma companies do little new drug innovation - STAT Gene Therapy Takes Center Stage at 2019 NORD Summit - Pulmonary Hypertension News People Living With Type 2 Diabetes Want Information and Empathy From Their Doctors More Than New Medications - PRNewswire Analysis: Large pharma companies do little new drug innovation - STAT Posted: 10 Dec 2019 01:51 AM PST L arge pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug development and the discovery of new medicines, and thus lead to a decline in drug innovation. If that argument is credible, there should be evidence to show that the large pharmaceutical companies are responsible for discovering innovative new drugs. To test that claim, we examined the...
Read more